Targeted therapy in the treatment of solid tumors: Practice contradicts theory

@article{Zhukov2008TargetedTI,
  title={Targeted therapy in the treatment of solid tumors: Practice contradicts theory},
  author={N. V. Zhukov and S. A. Tjulandin},
  journal={Biochemistry (Moscow)},
  year={2008},
  volume={73},
  pages={605-618}
}
The basic principle of targeted therapy formulated about ten years ago consists in the design and application of drugs specifically directed against well-defined targets that are critical for tumor survival and not compromising for normal organs and tissues. The past decade has been marked by the appearance of an immense diversity of novel antitumor agents with claimed targeted action. Unfortunately, despite indisputable progress in clinical settings, some popular drugs against solid tumors (e… 
Engineered Nanoparticles for the Delivery of Anticancer
TLDR
The present review focuses the on the basic pathophysiology of cancer and the various types of nanoparticulate drug delivery systems that have been explored so far, taking advantage of the tumour vasculature and other molecular mechanisms which differentiates cancer cells from normal ones, for the delivery of anticancer therapeutics for effective management of cancer.
Pharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice
TLDR
Since PSMA is also broadly expressed on the neovasculature of most tumors, it is expected YC-27 will have clinical utility for image-guided surgery and tumor resections and is developed and characterized.
Cancer gene expression profiles associated with clinical outcomes to chemotherapy treatments
TLDR
A database of gene expression profiles associated with clinical responses on chemotherapy for 2786 individual cancer cases, finding datasets suitable to build ML models for predicting responses on certain chemotherapeutic schemes.
Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization.
TLDR
The great potential of ATM and MRN complex inhibitors, including telomelysin, as radiosensitizing agents are highlighted.
ERBB oncogene proteins as targets for monoclonal antibodies
General properties of the family of tyrosine kinase ERBB receptors are considered in connection with their role in the generation of cascades of signal transduction in normal and tumor cells. Causes
Assessing efficacy and molecular mechanisms of curcumin in targeting cancer stem-like cells in colorectal cancer
II Acknowledgements III List of Figures X List of Tables XIV List of Abbreviations XV List of Publications XVIII List of Conference Abstracts XIX 1. Chapter one: Introduction 1 1.1. Cancer Statistics
...
...

References

SHOWING 1-10 OF 71 REFERENCES
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
TLDR
The results of this pilot study argue against trastuzumab activity in patients through down-modulation of HER2 but in favor of antibody-dependent cellular cytotoxicity guiding efforts to optimize the use of trastzumab in breast cancer patients.
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.
TLDR
The results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens, and the advantages of reduced toxicity, increased efficacy in some cases, and ability to combine chemotherapy administered long term with targeted therapies can be compromised.
Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
TLDR
BV has single agent activity in women with PROC, but is associated with substantial toxicity in this population, and trials are ongoing in less heavily treated, newly diagnosed pts with OC to evaluate the efficacy and safety of BV in these disease settings.
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
TLDR
The biology of EGFR in NSCLC, the clinical and molecular predictors of benefit from treatment with EGFR TKIs, the use of patient-specific molecular profiling, and future directions of clinical and basic scientific research are summarized.
Why the epidermal growth factor receptor? The rationale for cancer therapy.
TLDR
The rationale for EGFR-targeted approaches to cancer treatment is apparent and now well established, and there is increasing evidence that they may represent a significant contribution to cancer therapy.
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
TLDR
Continuously low-dose CTX and MTX is minimally toxic and effective in heavily pretreated breast cancer patients and alternative hypotheses, other than that of direct toxicity on tumor cells, must be favored when trying to explain the anticancer effect.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
  • M. Cobleigh, C. Vogel, D. Slamon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
  • C. Vogel, M. Cobleigh, M. Press
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.
Erlotinib in previously treated non-small-cell lung cancer.
TLDR
Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
TLDR
This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
...
...